A B S T R A C T Although mediator release from mast cells and basophils plays a central role in the pathogenesis of human allergic disease, biochemical studies have been restricted to rat peritoneal mast cells and basophilic leukemia cells because they could be easily purified. We have used two new techniques of cell separation to purify human lung mast cells to 98% homogeneity. Lung cell suspensions were obtained by dispersion of chopped lung tissue with proteolytic enzymes. Mast cells were then purified from the suspensions by countercurrent centrifugal elutriation and affinity chromatography. The purified mast cells released both histamine and slow-reacting substance of anaphylaxis (SRS-A) (leukotriene C and D) during stimulation with goat anti-human IgE antibody. Moreover, these preparations were able to generate significant quantities of SRS-A (32±7X 10-'7 LTD moleequivalents/mast cell) at all stages of purification, indicating that a secondary cell is not necessary for the antigen-induced release of SRS.
INTRODUCTION
Studies of respiratory allergic disease using chopped lung fragments have provided substantial insight into the mechanisms of mediator release by antigenic stimuli (1) . This system was modified by Lewis et al. (2) who introduced techniques to disperse the tissue into single cell suspensions using the proteases elastase, collagenase, chymopapain, and pronase. Single cell suspensions have allowed many manipulations that were tedious or impractical with chopped lung fragments. Lewis et al. (2) have also partially purified mast cells using isokinetic and isopycnic gradients. These tech-niques, however, only rarely resulted in mast cell purities >60%, which precluded many biochemical studies. We have developed an alternative procedure that uses the enzymatic dispersion of tissue followed by two newer techniques of cell separation that allow mast cells to be recovered at purities of >98%. We demonstrate here that the highly purified cells release both histamine and slow-reacting substance of anaphylaxis (SRS-A) ' Mast cell purification. Single cell suspensions of mast cells were obtained by enzymatic dispersion of chopped lung fragments using a modification of the procedure described by Lewis et al. (2) . The cell suspensions were further purified by centrifugal elutriation (Beckman JE-6 rotor, Beckman Instruments, Inc., Fullerton, CA; 1825 rpm, flow rates 11-30 ml/min.) that resulted in purities of 15-46% (mean+SEM: 26±3%, n = 20). Elutriation (3) is a negative selection pro-'Abbreviations used in this paper: BPO-FLYS, N-benzylpenicilloyl E-N-a-formyl-L-lysine; BPO-HSA, N-benzylpenicilloyl-1-human serum albumin; PG, prostaglandin; PIPES, piperazine-N,N '-bis-2-ethanesulfonic acid; SRS-A, slow-reacting substance of anaphylaxis.
cedure that separates cells according to their size; a major advantage of this technique is that cells are exposed only to isotonic buffer during centrifugation. The cells were then passively sensitized with purified penicillin (BPO)-specific IgE antibody (6, 000 ng/ml) as described previously for basophils (4), washed, and loaded onto a penicillin-Sepharose 6MB column. Most nonmast cells were washed from the column with buffer (4) after which the bound mast cells were eluted from the beads with buffer containing monovalent penicillin (2 mM N-benzylpenicilloyl-N-formyl-L-lysine [BPO-FLYSJ). The resulting suspensions consisted of 60-98% mast cells (mean±SEM: 81±3%, n = 20) that, by several criteria, including dye exclusion and electron microscopy (kindly performed by Dr. Ann Dvorak and Kathryn Pyne), were intact and functional (Fig. 1) . A full description of the procedures for mast cell purification will be published elsewhere (5) .
Leukotriene release. Mast cells at various stages of purification were suspended in PAGCM so that the mast cell concentration ranged from 1 to 3 X 106/ml. Usually 200 ,l of suspension was challenged with either 200 MA of control buffer, containing normal goat serum or anti-IgE antibody (quantity as indicated in Table I ). After 15-40 min small aliquots were removed for determination (6, 7) of histamine release and the reactions stopped by centrifugation and removal of the supernatant. The biological activity of the mast cell supernatant solutions was measured on the terminal segments of guinea pig ileum. Ileal strips were suspended in organ baths containing Tyrode's solution equilibrated with 95% 02-5% C02. The buffer contained atropine sulfate (Sigma Chemical Co.) (5 X 10' M) and diphenhydramine (Sigma Chemical Co.) (106 M). Contractions were measured with Grass FTO3C force-displacement transducers and were recorded on a Grass polygraph (Grass Instrument Co., Quincy, MA). Leukotriene standards were used to establish a calibration curve in each experiment. Results were calculated as LTD equivalents. In preliminary experiments with atropinized ileum in the absence of an antihistamine, we found that a standard unit of LTD activity (contraction equal to that by 5 ng/ml histamine) was achieved with -2 pmol LTD/ml, although this value was somewhat variable. Two ileal segments were studied simultaneously.
LTC and LTD measurements were also made by a radioimmunoassay (RIA) developed by Dr. Hayes and Dr. Rosenthal of the Merck Research Institute (submitted for publication). This RIA uses a rabbit antibody, having a titer of -1:25,000, which is specific for leukotrienes C and D with slight cross-reactivity with LTE. Concentrations of leukotrienes that produce 50% inhibition of binding are 7, 12.5, and 100.5 pmol/ml for LTC4, LTD4, and LTE4, respectively. Arachidonic acid, prostaglandin F2a (PGF2a), prostaglandin E2 (PGE2), and glutathione cross-react <10% at 7 nmol/ml and 5-hydroxy eicosatetranoic acid and fully reduced LTC4 cross-react <5% at 0.7 nmol/ml. The radiolabel was a tritiated LTC4 and unlabeled standard was provided by Dr. Rokach. Although all the data shown in the results section were derived from assays of SRS-A activity on the ileum approximately half of the samples were also run in the RIA to confirm these results.
RESULTS
Mast cells of purities up to 98% were examined for their ability to release histamine and SRS-A. Fig. 2 shows a tracing of the response of guinea pig ileum (Table I ). The anti-IgE antibody dose response of SRS-A release paralleled that for histamine release (data not shown). In experiment 9 the mast cells were challenged with the antigen, N-benzylpenicilloyl-human serum albumin (BPO-HSA), at a concentration optimal for histamine release. In this same experiment we found that cells desensitized with BPO-HSA (8, 9) failed to release either histamine or SRS-A upon rechallenge with BPO-HSA (data not shown).
In the four experiments shown in the bottom half of Table I , mast cells from the same lung were challenged at various stages of purification. In each case the production of LTD-equivalents/mast cell was not influenced by the presence of other cell types; i.e., preparations of mast cells at low purity produced no more SRS than highly purified mast cells. In experi- ments 10-12 the impure cells had not been passively sensitized before challenge (in contrast to purified cells that must be sensitized to be affinity purified) and histamine release was found to be slightly lower. We therefore repeated those experiments but also sensitized the low purity cells. In experiment 13 we found that purified cells release, if anything, more SRS-A than impure cells.
In 17 experiments (13 unrelated to the experiments in Table I ) the ratio of LTC/D concentrations determined by RIA and those determined by the bioassay was 1.15±0.14. For example the values determined by RIA for supernatants from experiments 7, 9, Ila and b were 54, 2.7, 19, and 33 LTD mole-equivalents/mast cell. Furthermore, all supernatants that had undetectable concentrations of LTD (controls and nonreleasing preparations) as determined by the bioassay also had undetectable or very low values by the RIA.
DISCUSSION
The contractile response of airways to antigenic challenge results not only from the release of histamine from mast cells but also from the generation of lipoxygenase products of arachidonic acid, principally leukotrienes C and T) (SRS-A) (10) , by cells that are presently undefined. Whether rat peritoneal mast cells are able to generate SRS is not clear (11) (12) (13) . With respect to human lung mast cells it has been found that as they are purified by density gradient centrifugation from 5 to 70% their ability to generate SRS decreases (14) . It has therefore been suggested that the production of leukotrienes C and D requires a secondary cell, perhaps the interstitial macrophage (14) . We found, however, that human lung mast cells do release significant quantities of SRS-A and that the production of LTDequivalents/mast cell did not change as mast cells from the same lung were purified from 3 to 98%. This material is identified as LTC or D based on the characteristics of the ileum contraction curve (slow), the ability of FPL 55712 to inhibit the ileal contraction, and its detectability by an RIA specific for LTC and LTD.
Whether the mast cell generates all of the SRS-A released from antigen-stimulated chopped lung is not clear. Parallel experiments with chopped lung were not performed but chopped lung fragments have been reported to generate 15-20 units of SRS-A/g of tissue (15) . Based on the data from 98% mast cells (experiment 1 in Table I Because highly purified human mast cells have not been available, mediators generated by antigenic challenge of chopped lung could not be unambiguously assigned to the mast cell. Moreover, direct biochemical studies on human material could not be carried out. Since strategies for the pharmacologic control of the human allergic response must be based on an appreciation of the release mechanism and the source of various mediators, the availability of highly purified human mast cells may be expected to have important consequences.
